Limiting tariffs on medtech products remains a priority for advocacy organization AdvaMed, president Scott Whitaker said during a Jan. 21 media briefing. The call was held to introduce new AdvaMed chairman of the board Mick Farrell, ResMed’s CEO and a member of the AdvaMed board since 2015.
Whitaker acknowledged that the Trump administration’s tariff policy “has not necessarily landed where we had originally hoped it would.” But ongoing conversations with administration officials remain productive, he said.
“On the question of, are they listening? The answer is yes,” he said. “Have they changed policy based on that? Not necessarily, and I think that’s an ongoing discussion we’re continuing to have with them.”
AdvaMed’s goal, he said, remains a “zero for zero” policy that would exempt medical devices from tariffs when they are sold to a country that does not impose its own tariffs on the products. While Whitaker conceded that this preferred approach did not align with Trump’s trade policy, a “stable policy environment” that would allow global medtech firms to plan based on an established tariff level remains within reach, he said.
Limiting tariffs on medtech products remains a priority for advocacy organization AdvaMed, president Scott Whitaker said during a Jan. 21 media briefing. The call was held to introduce new AdvaMed chairman of the board Mick Farrell, ResMed’s CEO and a member of the AdvaMed board since 2015.
Whitaker acknowledged that the Trump administration’s tariff policy “has not necessarily landed where we had originally hoped it would.” But ongoing conversations with administration officials remain productive, he said.
“On the question of, are they listening? The answer is yes,” he said. “Have they changed policy based on that? Not necessarily, and I think that’s an ongoing discussion we’re continuing to have with them.”
AdvaMed’s goal, he said, remains a “zero for zero” policy that would exempt medical devices from tariffs when they are sold to a country that does not impose its own tariffs on the products. While Whitaker conceded that this preferred approach did not align with Trump’s trade policy, a “stable policy environment” that would allow global medtech firms to plan based on an established tariff level remains within reach, he said.
